Last updated: 2026-09-16 12:18:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
TScan Therapeutics, Inc. (TCRX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.32, with a market capitalisation of $20.76M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.29 to $2.57. This page covers its latest market performance, valuation, price trends and company information.
$20.76M | |
$0.31 | |
$26.80 | |
$0.29 | |
$0.32 | |
12.88K | |
841.49K | |
-- | |
$2.57 | |
$0.29 | |
-- | |
-- |
TScan Therapeutics, Inc. (TCRX) is trading at $0.32 in pre-market trading as of 2026-09-16 12:13:00, up 0.22% ($0.00) from the previous close of $0.32
Pre-market trading shows how investors are pricing TCRX before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, TScan Therapeutics, Inc. (TCRX) moved from $0.39 to $0.32, representing a decline of 17.75% ($0.07).
The stock traded between $0.29 and $0.42 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.05 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1.4%
TCRX is currently trading at $0.32, placing it 1.4% of the way from its 52-week low of $0.29 to its 52-week high of $2.57. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 142 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of TScan Therapeutics, Inc. (TCRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.